Table 2 Prognostic analysis of characteristics and lymphocyte subsets in patients with PCa

Age, years

1.10

1.04 to 1.17

< 0.001

1.10

1.03 to 1.16

T stage

 T0-T1

Reference

 T2-T4

2.45

0.94 to 6.33

0.065

1.75

0.91 to 6.43

N stage

 N0, Nx

Reference

 N1

0.95

0.46 to 1.96

0.881

M stage

 M0, Mx

Reference

 M1

2.07

1.10 to 3.89

0.024

Total CD3(+) T lymphocytes, cells/µL

 < 1203.05

Reference

 ≥ 1203.05

0.45

0.20 to 1.01

0.053

CD3(+) CD4(+) T lymphocytes, cells/µL

 < 365.1

Reference

Reference

 ≥ 365.1

0.36

0.18 to 0.74

0.006

0.30

0.14 to 0.65

CD4(+)/CD8(+) ratio

 < 1.10

Reference

Reference

 ≥ 1.10

0.39

0.20 to 0.74

0.004

0.47

0.24 to 0.93

Total CD19(+) B lymphocytes, cells/µL

 < 45.83

Reference

 ≥ 45.83

0.35

0.18 to 0.68

0.002

CD19(+) CD5(+) B lymphocytes, cells/µL

 < 5.76

Reference

 ≥ 5.76

0.33

0.15 to 0.68

0.003

CD3(-)CD16(+)CD56(+) NK cells, cells/µL

 < 238.87

Reference

Reference

 ≥ 238.87

1.73

0.91 to 3.30

0.095

2.29

1.14 to 4.62